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Abstract 
In the last decades, the development of new technologies applied to lipidomics has revitalized the analysis of lipid 
profile alterations and the understanding of the underlying molecular mechanisms of lipid metabolism, together with 
their involvement in the occurrence of human disease. Of particular interest is the study of omega‑3 and omega‑6 
long chain polyunsaturated fatty acids (LC‑PUFAs), notably EPA (eicosapentaenoic acid, 20:5n‑3), DHA (docosahex‑
aenoic acid, 22:6n‑3), and ARA (arachidonic acid, 20:4n‑6), and their transformation into bioactive lipid mediators. In 
this sense, new families of PUFA‑derived lipid mediators, including resolvins derived from EPA and DHA, and protec‑
tins and maresins derived from DHA, are being increasingly investigated because of their active role in the “return to 
homeostasis” process and resolution of inflammation. Recent findings reviewed in the present study highlight that the 
omega‑6 fatty acid ARA appears increased, and omega‑3 EPA and DHA decreased in most cancer tissues compared 
to normal ones, and that increments in omega‑3 LC‑PUFAs consumption and an omega‑6/omega‑3 ratio of 2–4:1, are 
associated with a reduced risk of breast, prostate, colon and renal cancers. Along with their lipid‑lowering properties, 
omega‑3 LC‑PUFAs also exert cardioprotective functions, such as reducing platelet aggregation and inflammation, 
and controlling the presence of DHA in our body, especially in our liver and brain, which is crucial for optimal brain 
functionality. Considering that DHA is the principal omega‑3 FA in cortical gray matter, the importance of DHA intake 
and its derived lipid mediators have been recently reported in patients with major depressive and bipolar disorders, 
Alzheimer disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The present study reviews the relationships 
between major diseases occurring today in the Western world and LC‑PUFAs. More specifically this review focuses 
on the dietary omega‑3 LC‑PUFAs and the omega‑6/omega‑3 balance, in a wide range of inflammation disorders, 
including autoimmune diseases. This review suggests that the current recommendations of consumption and/or sup‑
plementation of omega‑3 FAs are specific to particular groups of age and physiological status, and still need more fine 
tuning for overall human health and well being.
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Introduction
The term ‘omics’ and the technologies associated with 
have expanded rapidly with the completion of the human 
genome in the early 2000s. “Genomics”, which refers to 
the multidisciplinary technology developed to deter-
mine the structure, function, evolution, and mapping 
of genomes was the initial “omic” [1]. This was followed 
by many others, such as transcriptomics, proteomics 
and peptidomics, metabolomics, and lipidomics [2, 3]. 
The latter is a subset of the metabolomics, and aims at 
mapping, determining and quantifying all lipids within 
healthy or altered cells, tissues or organisms [4, 5].
Lipidomics emerged about 15  years ago, and its pro-
gress has depended directly on the advances made in 
analytical technologies, particularly gas chromatogra-
phy (GC) and liquid chromatography (LC). The ability of 
both techniques to be coupled with mass spectrometry 
(MS) and the different ionization technologies developed 
including electrospray ionization (ESI), matrix-assisted 
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laser desorption/ionization (MALDI), and atmospheric 
pressure chemical ionization (APCI) has vastly improved 
their sensitivity. Other techniques, such as nuclear mag-
netic resonance (NMR), have also been utilized. All are 
accompanied by robust software to process the vast 
amounts of data collected [6, 7]. Thus, the field of lipid 
research is clearly advancing in parallel with the progress 
of analytical techniques. These advances allow the deter-
mination of lipid profile alterations and how these are 
associated with diseases. They can also detect changes in 
lipid metabolism or pathway modulation by lipids, that 
can now be established even in complex biological sys-
tems. This provides new insights, enabling the discovery 
and characterization of molecular biomarkers, as well as 
the understanding of various pathologies associated to 
lipids and their mechanisms, for the subsequent restora-
tion of lipids, prevention, drugs design and treatment of 
these ailments by acting on the lipid impact or alteration.
Lipids are natural products derived from polyke-
tides, which in turn originate from the acetate route 
[8]. The term lipids, includes fatty acids (FAs) and their 
derivatives, as well as related functional or biosynthetic 
substances derived from these compounds. Lipids are 
indispensable elements in the diet, both for the provi-
sion of energy (beta-oxidation of FAs), and for the supply 
of essential FAs, i.e. ALA (alpha-linolenic acid, 18:3n-3) 
and LA (linoleic acid, 18:2n-6) [9]. They have biological 
activities that act to influence the function and respon-
siveness of cell membranes and tissue metabolism, to 
hormonal and other signals. These biological activities 
may be grouped as regulation of membrane structure and 
function, regulation of intracellular signalling pathways, 
transcription factor activity together with gene expres-
sion, and regulation of the production of bioactive lipid 
mediators. Through these actions, FAs affect health, well-
being, and the risk of developing disease [10].
FAs are the simplest lipids, which in turn are compo-
nents of other more complex lipids. FAs are organic com-
pounds containing a hydrophilic carboxyl group attached 
to a hydrocarbon chain varying from C6 (six carbon 
atoms) to C32, with an additional terminal methyl group. 
Most of the FAs existing in nature have an even number 
of carbon atoms and linear hydrocarbon chains, although 
some of them, found primarily in bacteria, may contain 
branching or even cyclic structures [8]. In addition, these 
chains may be presented in two main forms, saturated 
without the presence of double bonds, or unsaturated, 
containing one or more double bonds, the latter being of 
greater physiological importance because of their medic-
inal properties. Of particular interest within the unsatu-
rated family are the long chain polyunsaturated FAs 
(LC-PUFAs), which can be categorized into two principal 
families—omega-3 (n-3) and omega-6 (n-6)—depending 
on the position of the first double bond from the methyl 
end group of the FA. Common LC-PUFAs are EPA 
(eicosapentaenoic acid, 20:5n-3), DHA (docosahexaenoic 
acid, 22:6n-3) and ARA (arachidonic acid, 20:4n-6).
The synthesis of FAs can proceed either by anaerobic 
routes through polyketide synthase enzymes, which are 
only present in some microorganisms, or by aerobic met-
abolic pathways, which are more universal, as they occur 
in plants, algae, fungi, and animals. This consists of suc-
cessive elongation (carbon chain elongation) and desatu-
ration steps (inclusion of double bonds into the carbon 
chain), reactions controlled by elongase and desaturase 
enzymes [11] (Fig. 1).
There are variations in the order in which the steps of 
desaturation and elongation occur. Thus, “metabolic path-
way 6” begins with a ∆6-desaturation, followed by chain 
elongation and desaturation thereof, to yield EPA when 
the initial substrate is ALA, or to yield ARA when the ini-
tial substrate is LA. Next, EPA is elongated to DPA (doc-
osapentaenoic acid, 22:5n-3), which is desaturated again 
in the 4-position to finally produce DHA (Fig.  1). There 
also exists the so-called Sprecher’s route, which describes 
the production of DHA by consecutive Δ6 and Δ5 desatu-
rations of ALA, to produce C24 metabolic intermediates 
that are finally shortened to DHA by a β-oxidation step 
that takes place in the peroxisomes [12]. What defines 
this route, which has been characterized in mammals 
and fish [13, 14], is that the final product, DHA, is syn-
thesized without the intervention of the Δ4-desaturase. 
Finally, the “alternative route 8”, typical in protists and 
algae, begins directly with an elongation step from C18 
to C20, followed by desaturations at positions 8 and 5, 
generating DGLA (dihomo-γ-linolenic acid, 20:3n-6) and 
ARA, respectively, as well as to finally produce ETA (eico-
satetraenoic acid, 20:4n-3) and EPA [15] (Fig. 1).
Diet, among other factors, has been postulated to 
modulate human capacity to produce LC-PUFAs from 
their essential C18 FA precursors, i.e. ALA and LA [16]. 
However, most recent studies indicate that endogenous 
synthesis of DHA from ALA in humans is much lower 
and more limited than previously assumed [17, 18] and 
as a consequence, sources of n-3 LC-PUFAs such as fish 
should be included in the human diet for general health 
[19, 20].
Thereby, with the technical advances attained in the 
last decades, and the deeper understanding of cell mem-
brane physiology, lipids have eventually gained impor-
tance in maintaining health, and more importantly, in 
their involvement in the development of diseases. In this 
review, we demonstrate the use of lipidomics and the cor-
responding analytical tools to highlight the most recent 
information and evidences that LC-PUFAs participate in 
several major human pathologies.
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Inflammatory‑autoimmune diseases and lipids
Virtually all diseases including diabetes and obesity, can-
cer and cardiovascular, and neurodegenerative diseases, 
manifest some symptoms of inflammation. Other disor-
ders classified under the term of inflammatory diseases, 
such as allergies, asthma, arthritis and autoimmune dis-
eases, are dramatically increasing in occurrence. Possible 
causes of these inflammatory conditions are pointing to 
some novel factors, such as hidden allergens and infec-
tions, environmental and dietary toxins, intake of pro-
inflammatory diets, and even sustained stress.
Western countries seem to be facing epidemics of aller-
gic (60 million people), asthmatic (30 million people) and 
autoimmune disorders (24 million people), which include 
a wide variety of syndromes affecting all together around 
5 percent of the total Western population [21, 22]. Rheu-
matoid arthritis, lupus, multiple sclerosis, psoriasis, 
celiac disease, inflammatory bowel disease, ulcerative 
colitis, Crohn’s disease and thyroid disease, are just some 
of the ailments that belong to this poorly understood 
group of diseases. They are twenty first century illnesses 
that mostly occur in developed countries.
Autoimmune disorders are characterized by a systemic 
inflammation, which results in the body attacking its 
own tissues. In the absence of an infection or other clear 
reason, the activation of T cells or B cells or both, gives 
rise to this clinical condition. It seems that women are 
more susceptible to suffer from autoimmune diseases, 
Fig. 1 Biosynthetic route of fatty acids requiring the essential LA (linoleic acid) and ALA (alpha‑linolenic acid) with the different variations and steps. 
des desaturase, elo elongase; ARA (arachidonic acid), DGLA (dihomo‑gamma linolenic acid), DHA (docosahexaenoic acid), DPA (docosapentaenoic 
acid), DTA (docosatetraenoic acid), EPA (eicosapentaenoic acid), ETA (eicosatetraenoic acid), GLA (gamma‑linolenic acid), SDA (stearidonic acid)
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and that environmental factors and alien substances may 
act as haptens and render autoantigens immunogenic. 
Autoimmune syndromes and their multifarious and still 
unknown foundations are a challenge to the progress and 
testing of new therapies to fight disease [22, 23].
Although an attempt to decrease total fat and satu-
rated fat intake in Western diets has become a dietary 
tonic, with evolution, the intake of omega-6 FAs has 
increased while that of omega-3 FAs has decreased. As 
a result, the omega-6/omega-3 ratio has substantially 
risen from 1:1 in our ancestral diets, to around 20:1 in 
today’s Western diets. This change also coincides with 
a significant increase in the prevalence of overweight 
and obesity, together with a wide range of inflamma-
tion disorders. However, controversial results have been 
reported regarding the influence of the dietary ratio of 
omega-6/omega-3 FAs on body fat increments, mecha-
nisms of adipogenesis, browning of adipose tissue, lipid 
homeostasis, brain–gut-adipose tissue axis, and systemic 
inflammation [24, 25].
The reduction of inflammation observed in clinical 
studies with supplemental omega-3 LC-PUFAs opens 
new options to pharmacologically treat systemic lupus 
erythematosus [26]. Additionally, animal models dem-
onstrate the benefits of n-3 FAs in rheumatoid arthritis 
(RA), inflammatory bowel disease (IBD) and asthma. 
Whereas results using supplemental fish oil in patients 
with IBD are still unreliable, clinical trials involving 
patients with RA have demonstrated benefits that have 
been further supported by meta-analyses studies [27].
Globally, experimental results highlight that a wide 
number of inflammation-related events can be partly 
impeded by a dietary intake of EPA and DHA from 
oily fish and fish oil supplements. As Calder elegantly 
revised [28, 29], these events include leukocyte chemo-
taxis, cellular adhesion molecule (CAM) expression, 
leukocyte–endothelial adhesive interactions, produc-
tion of ARA derived eicosanoids like PGs and LTs, pro-
duction of inflammatory cytokines and T cell reactivity. 
Mechanisms underlying the anti-inflammatory actions 
of n-3 LC-PUFAs also include: alteration of cell mem-
brane phospholipid FA composition, disruption of lipid 
rafts, inhibition of the activation of the pro-inflammatory 
nuclear transcription factor kappa B (NF-κB), activation 
of the anti-inflammatory transcription factor NR1C3 (i.e. 
peroxisome proliferator activated receptor), and binding 
to the G protein coupled receptor GPR120. Mechanisms 
which are all interlinked.
PUFAs can regulate a wide set of homeostatic and 
inflammatory processes linked to numerous diseases 
either directly or via transformation into locally act-
ing bioactive metabolites [30]. These metabolites are 
products of reactions with cyclooxygenases (COX1 and 
COX2), lipoxygenases (LOX), cytochrome p450 (CYP-
450), or other downstream enzymes, such as soluble 
epoxide hydrolase (sEH) and non-enzymatic reactions 
[31–34] (Fig.  2). The physiological functions of these 
PUFA-derived lipid mediators are only well understood 
for a few molecules. It seems that some of the ago-
nists and receptors that regulate inflammation, and the 
cytokine cascade that accompanies infection, initiate the 
release of ARA and related PUFAs, resulting in a lipid 
bioactive signalling storm [35–37].
Classically, the term eicosanoids has been used to 
describe not only those metabolites derived from ARA, 
but also from other 20 carbon PUFAs, such as EPA and 
DGLA. Eicosanoids include the COX products prosta-
glandins (PGs), prostacyclin (PGI) and thromboxanes 
(TXs); the LOX derived leukotrienes (LTs) and lipoxins 
(LXs), and the CYP-450 hydroxyeicosatetraenoic acids 
(HETEs) and epoxyeicosatrienoic acids (EETs) (Fig.  2). 
Eicosanoids derived from omega‐6 PUFAs (i.e. ARA 
products  PGE2 and  LTB4) are more powerful than their 
omega-3 PUFAs counterparts (i.e. EPA derived  PGE3 
and  LTB5), which exert anti-inflammatory effects. SDA 
(stearidonic acid, 18:4n-3) and its elongated product 
20:4n-3, have been reported to produce low active and 
health promoting eicosanoids able to lower plasma tri-
glycerides (TG) [38].
Not only the absolute amounts of omega-6 and 
omega-3 FA intake, but also the above mentioned 
increased omega-6/omega-3 ratio, have been recently 
shown to be highly pro-thrombotic and pro-inflamma-
tory, and contribute to the prevalence of atherosclerosis, 
obesity, diabetes and inflammatory-autoimmune diseases 
[25]. The larger the intake of ARA or its C18 precursor 
LA, the higher the production of their respective derived 
pro-inflammatory eicosanoids.
In the last two decades, new families of lipid mediators 
important in the resolution of inflammation have been 
discovered and are being investigated. Thus, resolvins, 
protectins and maresins (Fig.  2) have been identified 
in the resolving exudates of acute inflammation. EPA-
derived E-series (RvE) and DHA-derived or D-series 
(RvD) resolvins display potent anti-inflammatory and 
immunoregulatory actions that include blocking the pro-
duction of pro-inflammatory mediators and regulating 
trafficking of leukocytes [34]. In addition to the D-series 
resolvins, DHA is also a precursor of other anti-inflam-
matory docosanoids named protectins (PDs) and mares-
ins. These pro-resolving lipid mediators, together with 
the above mentioned resolvins, and the anti-inflamma-
tory lipoxins, have been grouped together as specialized 
pro-resolving mediators (SPM). These are interesting 
compounds that constitute a novel topic of research, 
not only due to their bioactive role in the “return to 
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homeostasis” process, but also elucidating the physiologi-
cal functions of other n-3 LC-PUFAs. In this sense, SPMs 
could be responsible for the efficacy of n-3 LC-PUFAs in 
the prevention and amelioration of childhood asthma, 
food allergies or atopy [39].
Metabolism of most eicosanoids/docosanoids implies 
the release of FAs esterified into phospholipids, by phos-
pholipase A2 (PLA2) enzymes. Consequently, increased 
levels of free FAs and lipid mediator biosynthesis occur 
particularly after inflammatory cell activation. The most 
frequently involved PLA2s in the cellular production of 
bioactive lipids are, the cytosolic calcium-dependent 
PLA2 (cPLA2), the cytosolic calcium-independent PLA2 
(iPLA2), and the secretory PLA2 (sPLA2). Among them, 
cPLA2, shows a preference to hydrolyse ARA in the sn-2 
position of phospholipids, and is generally considered the 
dominant enzyme mediating production of pro-inflam-
matory eicosanoids, as well as the release of related n-3 
PUFAs, i.e. EPA, DPA and DHA bioactive derivatives. In 
contrast, through the production of lysophospholipids 
iPLA2 plays a key role in most daily cellular functions, 
particularly in membrane homeostasis and remodelling. 
Finally, it remains unclear what role sPLA2 may play in 
eicosanoids signalling, although a cPLA2-dependent 
increase in the magnitude and duration of free FA levels, 
including ARA caused by sPLA2 up-regulation has been 
recently proposed [37, 40].
As already mentioned, the eicosanoids derived from 
ARA as a substrate are generally far more potent as pro-
inflammatory and pro-thrombotic signalling regulators 
than those from EPA and DGLA. PGE2 and LTB4 in par-
ticular induce the production of interleukins IL-6 and 
IL-1β, and tumour necrosis factor (TNF). It is also known 
that the mechanism for PGE2-induced IL-6 production 
is via direct activation of the nuclear transcription fac-
tor kappa B (NF-κB). However, at the same time, DHA 
is a potent regulator of NF-κB by several mechanisms, 
since it can directly inhibit NF-κB activation, or prevent 
Fig. 2 Principal bioactive lipid mediators derived from ARA, EPA and DHA by the action of lipoxygenases (LOXs), cyclooxygenases (COXs), 
cytochrome P450 (CYP‑450) and soluble epoxide hydrolase (sEH). ARA (arachidonic acid), DHA (docosahexaenoic acid), DHET (dihydroxy‑
eicosatrienoic acid), DiHDPA (dihydroxy‑docosapentaenoic acid), DiHETE (dihydroxy‑eicosatetraenoic acid), EET (epoxy‑eicosatrienoic acid), EPA 
(eicosapentaenoic acid), EpDPE (epoxy‑docosapentaenoic acid), EpETE (epoxy‑eicosatetraenoic acid), HEPE (hydroxy‑eicosapentaenoic acid), HETE 
(hydroxy‑eicosatetraenoic acid), HpDHA (hydroperoxy‑docosahexaenoic acid), HpEPE (hydroperoxy‑eicosapentaenoic acid), HpETE (hydroperoxy‑
eicosatetraenoic acid), LT (leukotriene), LX (lipoxin), PG (prostaglandin), Rv (resolvins), TX (thromboxane)
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its activation by up-regulating intracellular glutathione 
to levels that effectively balance the oxidative stress. 
Furthermore, indirect mechanisms for DHA include its 
oxidation to the above mentioned potent signalling mol-
ecules, the resolvins. During conditions of tissue stress, 
both EPA and DHA may be released from phospholipids 
by PLA2 to undergo conversions to resolvins that actively 
promote the resolution of inflammatory processes. 
Known anti-inflammatory mechanisms for the resolvins 
include the down-regulation of NF-κB, and the removal 
of neutrophils from inflammatory sites [19].
Since the introduction of lipidomics, the expanded 
view of pro-inflammatory and anti-inflammatory con-
tributions of n-3 PUFAs derived eicosanoid/docosanoid 
signalling is remarkably more complex than initially 
thought. However, the potential to understand and 
develop novel treatments for proper inflammatory and 
metabolic conditions have become extremely promis-
ing. The beneficial properties of omega-3 FAs have been 
appreciated for many years. However, the use of new lipi-
domics analytical strategies, with increased sensitivity 
and throughput, has identified new FA-derived bioactive 
metabolites with new subjacent molecular mechanisms 
of action. Undoubtedly, this area of research has further 
highlighted the importance of eicosanoids in the inflam-
matory process, and in particular, the role of omega-3 
metabolites in controlling the inflammatory response 
and switching inflammation into a resolution state. In 
addition, it has also revealed the importance of gaining 
a ‘global’ view of eicosanoid and docosanoid metabolism 
in order to better understand the complex and exquisitely 
regulated mechanisms of their generation, action and 
metabolic inactivation, as well as an understanding into 
how these interconnecting and tightly regulated meta-
bolic pathways are deregulated in disease settings [41].
A better comprehension of the cytokine cascade and its 
integration with the eicosanoid and docosanoid eruption 
that accompanies inflammation and its resolution should 
provide new insights leading to novel strategies for the 
understanding and treatment of inflammation according 
to individual age, genetic variation or dietary regime [37]. 
Meanwhile, the tremendous importance of acquiring the 
beneficial omega-3 PUFAs through diet to mitigate or 
prevent the appearance of these ailments has also been 
presented.
Lipids and cardiometabolic health
Cardiovascular disease (CVD) was the leading global 
cause of death in 2013, claiming more lives each year 
than all forms of cancer and chronic lower respiratory 
disease combined. According to the last American Heart 
Association Heart Disease and Stroke Statistics Report, 
CVD accounted for over 17.3 million deaths per year 
globally, a number that is expected to grow above 23.6 
million by 2030 [42].
Several cardio-metabolic risk factors are associated 
with the prevalence of CVD, with only few of them, such 
as age, gender, genetics or family history, being non-
modifiable. Most well-established risk factors for CVD 
are behavioural or modifiable, and are the target of pre-
ventive or treatment interventions [43]. These risk factors 
include tobacco smoking, physical inactivity, inadequate 
diet, high blood pressure (SBP/DBP ≥140/90  mm  Hg) 
and those that fall under the umbrella of metabolic 
syndrome, i.e. high fasting plasma glucose (≥100  mg/
dL), dyslipidemia (triglycerides (TG) ≥150  mg/dL and 
HDL-C <40  mg/dL in males or <50  mg/dL in females), 
obesity (waist circumference >102 cm in males or >88 cm 
in females) and insulin resistance [42] (Fig. 3).
Within the possible lifestyle modifications for the pri-
mary and secondary prevention of CVD, following a 
cardioprotective diet constitutes one of the main recom-
mendations of many health and nutritional organizations 
and governing bodies. Consumption of fruits, vegetables, 
dietary fibre, and monounsaturated and polyunsaturated 
fats coming from sources such as fish, nuts, and vegetable 
oils, has been shown to have a protective effect [44].
Multiple observational studies and early-randomized 
clinical trials show an inverse relationship between the 
ingestion of marine derived omega 3 or n-3 LC-PUFAs 
and major cardiovascular adverse outcomes [45]. Recom-
mendations of n-3 LC-PUFAs intake from organizations 
Fig. 3 Scheme of cardio‑metabolic risk factors associated with the 
prevalence of cardiovascular disease (CVD)
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such as the International Society for the Study of Fatty 
Acids and Lipids (ISSFAL), the United Kingdom Scien-
tific Advisory Committee in Nutrition (SACN) and the 
American Heart Association (AHA) include the con-
sumption of 2–3 portions of oily fish per week in order to 
provide a minimum dietary intake of 200–500 mg/day of 
EPA plus DHA, increasing to 1–4 g/day for the secondary 
prevention of CVD or as a TG lowering therapy [46–48].
The capacity of n-3 LC-PUFAs to lower fasting plasma 
TG concentrations and VLDL production, one of the 
main TG-transporting lipoproteins, is one of the main 
proposed mechanisms that would explain omega-3 LC-
PUFAs cardioprotective role, and it is also one of the 
most consistent findings across studies. Taking EPA and/
or DHA in doses of 3.4–4  g/day have been shown to 
decrease TG levels by an average of 29% in individuals 
with levels higher than 150 mg/dL [49].
Proposed mechanisms to account for these effects 
include changes in transcription of several nuclear 
receptors involved in controlling lipid homeostasis: 
sterol regulatory element binding proteins (SREBP), 
liver X receptor-alpha (LXRα), retinoid X receptor 
alpha (RXRα), farnesoid X receptor (FXR), and peroxi-
some proliferator-activated receptors (PPARs). EPA and 
DHA have been shown to regulate SREBP1c expression 
by inhibiting binding of the LXR/RXR heterodimer to 
the LXREs in the SREBP-1c promoter. This inhibition 
is translated into a decrease in de novo lipogenesis and 
therefore, into a reduction of circulating TG levels [29, 
49].
PUFAs also inhibit transcription of HNF-4α, regulating 
fat and carbohydrate metabolism and bile acid synthesis. 
Binding of n-3 LC-PUFAs activate FXR, which reduces 
TG levels by increasing hepatic clearance through modu-
lating lipoprotein lipase activity, inducing PPARα, and 
inhibiting SREBP-1c. Importantly, activation of PPARα 
increases FA oxidation, lipoprotein lipase, FA transport 
and enhances adipocyte differentiation, all contributing 
to lowering TG [45].
Along with their lipid-lowering properties, omega-3 
LC-PUFAs exert other cardioprotective functions, i.e. 
reduction of platelet aggregation and inflammation, anti-
arrhythmic effect, improvement of endothelial function 
and myocardial relaxation and efficiency, stabilization of 
atherosclerotic plaques, and reduction of resting heart 
rate and systolic and diastolic blood pressure [50]. The 
beneficial effects of EPA and DHA in reducing hyper-
tension have been reported in both animal and human 
studies. Several meta-analyses of placebo controlled tri-
als show reductions in blood pressure in hypertensive, as 
well as in normotensive individuals [51].
With reference to other cardiovascular risks also asso-
ciated with CVD and metabolic syndrome, protection 
against the development of impaired glucose homeosta-
sis and insulin resistance has been reported in animal 
studies, especially in murine models of metabolic syn-
drome and type-2 diabetes. n-3 LC-PUFAs increase the 
expression of insulin-stimulated glucose transporter-4 
(GLUT4), insulin receptor substrate-1 (IRS1) and gly-
cogen synthase-1 (GYS1) in skeletal muscle, enhancing 
glucose utilization [52]. In humans however, it is still 
not clear whether n-3 LC-PUFAs have clinically relevant 
effects on insulin resistance or diabetes risk.
Regarding lipid mediators and CVD, as described pre-
viously, eicosanoids have been attributed to a diverse 
range of biological activities, with PGs, TBXs and LTs dis-
playing pro-inflammatory or pre-thrombotic roles.  PGE2, 
in addition of being involved in all processes leading to 
the classic signs of inflammation (redness, swelling, and 
pain); it is also known to play a key role in the pathogen-
esis of cardiovascular diseases, contributing to regula-
tion of blood pressure.  TXA2 has been shown to promote 
platelet aggregation, vasoconstriction, and smooth mus-
cle proliferation, while leukotriene LTB4 promotes ath-
erosclerosis [53]. However, not all ARA metabolites have 
a counterproductive effect, with some of them being able 
to display a beneficial/detrimental role depending on the 
tissue they are targeting or just having a general positive 
effect. In particular, ARA metabolites like EETs and their 
corresponding diols (DHETs), LXs and PGI2 have been 
understood to play a protective role in cardiovascular 
health (Fig.  2). Thus, EETs decrease inflammation and 
platelet aggregation, and in general act to maintain vas-
cular homeostasis, while DHETs have vascular activity in 
coronary arteries. LXs have a number of direct actions on 
endothelial cells that are protective, and are in line with 
their role in resolution. PGI2 potently inhibits platelet 
aggregation and displays powerful vasodilator effects via 
relaxation of smooth muscle [50, 54, 55].
In addition to this “classic” pathway, EPA and DHA are 
likely to have a further protective function in cardiovas-
cular health due to their ability to generate specialized 
pro-resolving mediators (SPMs) named resolvins, protec-
tins and maresins, which display an active role in the res-
olution of inflammatory processes, [56]. EPA and DHA 
also serve as substrates for CYP-450 and sEH enzymes, 
generating epoxides and diols similar in structure but 
more potent than their ARA analogues (Fig. 2). It appears 
that DHA-epoxides are particularly efficient in reducing 
angiotensin-II driven blood pressure [57], and can be fur-
ther metabolized to their corresponding diols, which are 
also vasomodulators and display direct effects on vascu-
lar smooth muscle tone [58].
Multiple epidemiological studies, prospective cohort 
studies and randomized controlled trials have provided 
evidence for the cardioprotective role of n-3 PUFAs. 
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However, the overwhelming beneficial outcome of early 
studies appears to conflict with the results of recent pro-
spective trials and meta-analysis of clinical trials, where 
mixed or less favourable results have been reported 
[59–61].
Back in 1970 epidemiological studies conducted in 
Greenland Inuits suggested that the high content of n-3 
LC-PUFAs in their diet could be associated with the 
decreased risk of cardiovascular events and cardiovas-
cular mortality observed in this population [62]. Follow-
ing these observations, several prospective studies were 
designed to study the effect of fish or fish oil consump-
tion on CVD. The DART study (Diet and Reinfarction 
Trial) enrolled male myocardial infarction (MI) survi-
vors who were given dietary advice to eat at least two 
servings of fatty fish/week or fish oil capsules (0.5 g/day) 
for 2 years [63]. The results from this study showed that 
fish oil consumption reduced mortality by 29%. Another 
major study, the GISSI (Gruppo Italiano per lo Studio 
della Sopravvivenza nell’ Infarto Miocardico-Prevenzione 
Trial) [64], showed an impressive reduction in both total 
and CVD mortality in post-MI patients taking 850  mg/
day of EPA/DHA in a 1:2 ratio. However, a follow up of 
this trial, the GISSI-Heart Failure study [65], investigated 
the effect of 1 g/day omega-3 PUFA in patients with heart 
failure, reported a smaller reduction in mortality com-
pared with the GISSI-P outcome.
The JELIS study (Japanese Eicosapentaenoic Acid Lipid 
Intervention Study), an open-label blinded trial con-
ducted with patients with hypercholesterolemia, showed 
that 1.8 g/day of EPA reduced combined cardiovascular 
events, although no effect on the incidence of arrhythmia 
was observed [66].
Recently, the double-blind Alpha-Omega Trial [67] 
indicated that an additional low-dose omega-3 supple-
mentation did not significantly reduce the rate of major 
cardiovascular events in post-MI patients who were 
receiving state-of-the-art antihypertensive, antithrom-
botic, and lipid-modifying therapy. However, a second-
ary analysis in those patients with diabetes suggested that 
those who received the EPA-DHA plus ALA treatment 
experienced less ventricular arrhythmia-related events, 
and less combined end-point ventricular arrhythmia-
related events. They also had a reduced number of fatal 
MIs [68].
In the last 7 years, other studies including the OMEGA 
trial, the SU.FO.OM3 trial, the ORIGIN study, the Risk and 
Prevention Study, and the AREDS2 trial have provided lit-
tle or no evidence that n-3 PUFAs consumption reduces 
cardiovascular events, mortality or morbidity [69].
An explanation of the discrepancy between the results 
obtained in early trials and more recent studies could be 
the differences in baseline levels of omega-3 and drug 
therapy status of participants. Most of the early stud-
ies were carried out in the pre-statins era and when 
consumption of fish oil was not as widespread, so it is 
understood that higher levels of n-3 PUFAs in the cur-
rent background diet and higher numbers of participants 
on CVD medications would make it more difficult for n-3 
PUFAs to display a significant effect on CVD outcomes.
In this regard, the erythrocyte membrane EPA and 
DHA content or omega-3 index has been proposed as 
an indicator of n-3 LC-PUFAs intake, and as a risk strati-
fication tool for coronary heart disease death. Setting 
an Omega-3 Index cut off or baseline level during the 
recruitment of participants would possibly allow out-
comes of prospective trials to be more pronounced [70].
With reference to the interaction of drugs used in sec-
ondary prevention of CVD and n-3 PUFAs, two clini-
cal trials are being conducted at present, the reduction 
of cardiovascular events with EPA-Intervention Trial 
(REDUCE-IT) and STRENGTH (Statin Residual Risk 
Reduction with Epanova in High Risk Patients with 
Hypertriglyceridemia) to provide further evidence of the 
effect of omega-3 supplementation and statin therapy in 
established CVD or high risk for CVD participants [69].
In addition to the assessment of the n-3 LC-PUFAs 
baseline levels and the clinical history/medication of the 
prospective participants, other aspects, such as the qual-
ity and stability of the n-3 LC-PUFAs sources, the bioavail-
ability achieved with the selected EPA and DHA chemical 
form, the selection of the most appropriate FA dosage to 
use, and the ideal EPA:DHA ratio when these FAs are used 
in combination, should be taken into account. Other fac-
tors as the improved digestion and absorption of these 
FAs when they are consumed along fatty meals, together 
with the selection of the most adequate study length and 
the use of compliance indicators during the course of the 
intervention, should carefully be weighed as important 
study design components that could possibly affect the 
overall outcome of future intervention trials.
Cancer and lipids
Cancer cells are known to exhibit a high and uncontrol-
lable capacity to divide and proliferate. They require cel-
lular building blocks, having an avidity for certain types 
of nutrients, particularly sugars, glutamine, nucleic acids, 
proteins and lipids, the latter being needed for the for-
mation of new membranes [71–73]. The high potential 
to boost angiogenesis or vascularization mechanisms for 
the progression of cancer is also well documented [74], as 
well as their metastatic faculty to invade healthy organs, 
with metastasis being the cause of 90% of deaths from 
solid tumours [75].
Regarding lipids, despite being ignored for a long time, 
an increasing number of reports are being made available 
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recognising the importance of these molecules within 
the cancer process where lipids, and in particular FAs, 
are required primarily for building new cell membranes. 
Cell membranes are composed of complex lipids, many 
of which are derived from palmitic acid (16:0). Lipids also 
act as biomolecules with ample signalling and transcrip-
tion capabilities. Interestingly there are marked differ-
ences in the lipid profiles of cancer cells compared with 
normal cells [76].
Like glutamine and lipids it has been agreed upon that 
cancer cells exhibit a high uptake of sugars, i.e. glucose, as 
an energy and building block molecule [71, 72, 77]. This 
sugar demand has served as a diagnostic tool in fluoro-
deoxyglucose positron emission tomography (FDG-PET) 
that can detect and image high glucose metabolism spots 
within the body [78].
Total sugar consumption positively correlated with the 
risk of esophageal adenocarcinoma; while added fructose 
was linked with an increased risk of small intestine can-
cer. In general, all investigated sugars were related to an 
increased risk of pleural cancer. Nonetheless, no relation 
between dietary sugars and risk of colorectal or any other 
major cancer was found [72]. A classical assumption has 
been that most proliferating cells rely on de novo synthe-
sis of lipids from sugars to make new cell walls. However, 
an elegant report exhibits the nutrient preferences of pro-
liferating fibroblasts and cancer cells in the presence of 
glucose and/or lipids (palmitate). Standard growth media 
for animal cells contain relatively low level of lipids, but 
large amounts of sugars and proteins. Employing this 
type of growth medium, fibroblast cells, HeLa and H460 
cancer cells rely primarily in de novo synthesis of lipids 
from glucose or glutamate. However, when exogenous 
palmitate was added to the culture medium, de novo syn-
thesis was very minor, showing a clear preference and 
marked uptake of palmitate (ca. 90%) from the medium 
for membrane formation. This evidence supports the 
importance of exogenous FAs to cellular proliferation. 
Moreover, blocking FA uptake decreased the prolifera-
tion of fibroblast, HeLa and H460 cells, and supplement-
ing them with exogenous palmitate, decreased lipogenic 
demand and dropped glucose uptake. These results sug-
gest that proliferating cells utilizing exogenous lipids 
would be less susceptible to drugs designed to inhibit gly-
colysis and/or lipogenesis for cancer treatment [73].
Cancer cells alter their metabolism to gain a continuous 
and potent proliferation capability. It has been cited that 
one major player is the modification of lipid metabolism, 
together with the reprogramming of lipid synthesis with 
the activation of many pathways and protein–protein 
interactions [79, 80]. Lipogenic enzymes, such as acetyl 
CoA carboxylase (ACC), fatty acid synthase (FASN), 
ATC citrate lyase (ACLY), are increased in most tumours 
[77, 81, 82]. FASN appears overexpressed in many cancer 
types including breast and prostate, suggesting that FA 
synthesis plays a crucial role in cancer development [79]. 
Similarly, FA β-oxidation enzymes, particularly carnitine 
palmitoyltransferase 1 isoforms, were also overexpressed 
in many human tumours [80], with the upregulation of 
the FA biosynthesis beginning at early stages in the can-
cer process in various types of cancers [77].
Analogously, some downstream cancer cell lipid 
metabolism transcription factors and signal regulating 
genes are overexpressed; in particular, FASN is controlled 
by growth factor receptor-associated signalling pathways, 
including the PI3K-Akt (phosphatidylinositol 3-kinase) 
and MAPK (mitogen-activated protein kinase), through 
the SREBP-1 transcription factor [77, 83]. SREBP pro-
teins are central for maintaining cellular lipid homeosta-
sis, and unusual activation of SREBPs can contribute to 
obesity, fatty liver disease, insulin resistance, and could 
also be involved in cancer development [83].
Cholesterol is an important component of biological 
membranes influencing the fluidity of the lipid bilayer. 
With the reprogramming of cancer cells lipid metabo-
lism, cholesterol synthesis is also affected; for example, in 
prostate and breast cancers. Its synthesis is highly regu-
lated and proceeds through the mevalonate pathway with 
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) 
being a rate-limiting step. HMGCR is the target for 
statins, which have been reported to show antiprolif-
erative activity in various cancer-cell lines, and have also 
been shown to increase the sensitivity to chemotherapy 
agents in colorectal cancer, and patients with acute mye-
loid leukaemia or hepatocellular carcinoma [79].
In cancer cells major changes in lipid composition, i.e. 
the presence and/or abundance of saturated vs unsatu-
rated FAs critically affects membrane physiology and 
plasticity. In bladder cancer tissue, levels of stearic acid 
(18:0), and oleic acid (18:1n-9) were higher compared to 
normal tissue, while the level of ARA was lower. Bladder 
cancer tissue showed a significant reduction in total n-6 
PUFAs (−15.1%). The change in the FA composition may 
be regarded as an indicator of altered lipid metabolism 
occurring in  vivo during human bladder tumorigenesis 
[84].
In multiple myeloma (MM) patients, significant differ-
ences in the plasma FA profile were observed compared 
to control. The total quantity of saturated and n-6 PUFAs 
in plasma were significantly higher in the MM group 
compared to the control group (28.0 vs 25.1%); and more 
strikingly, total n-3 FAs were significantly decreased in 
the plasma of patients with MM compared to control (7.7 
vs 14.5%). The MM group showed decreased ALA (1.7 
vs 6.0%), EPA (2.1 vs 3.8%), and DPA (0.3 vs 1.4%) lev-
els, as well as a clear drop of the n3/n6 ratio (0.3) with 
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respect to the control (0.6) [85]. Compared to normal 
tissue samples, breast cancer tissue samples had higher 
levels of monounsaturated FA (oleic acid) and ARA, and 
lower levels of LA. Furthermore, the breast cancer tissues 
showed a significantly higher monounsaturated FA/satu-
rated FA ratio [86].
Analogously, adipose tissue also influences cancer pro-
gression, particularly for its capacity to act as an endo-
crine system releasing and controlling biologically active 
substances (e.g. leptin, adiponectin, TNF-α, etc.) some 
of which are upregulated in cancer [87]. Moreover, the 
size and/or number of intracellular lipid stores, or lipid 
droplets, which mainly contain triacylglycerides and cho-
lesterylesters, are elevated in different types of tumours 
(breast, prostate, cervical, liver, colon) [79, 88].
Finally, n-3 LC-PUFAs exhibit anticancer activity, 
whereas n-6 LC-PUFAs promote the development of can-
cer [89]. Omega-3 LC-PUFAs consumption has been asso-
ciated with a reduced risk of breast, prostate, colon and 
renal cancers. On the other hand, the levels of n-6 ARA 
appeared to be increased in most cancer tissues, while the 
levels of EPA and DHA were found to be lower than in 
normal tissues [90]. Rather than individual FAs, the ratio 
n-6/n-3 is of crucial importance for maintaining a healthy 
status and for the prevention of cancer, with a 2−4:1 ratio 
being optimal [91]. The mechanisms involved in the cancer 
prevention of n-3 LC-PUFAs are thought to proceed via 
their anti-inflammatory effect, their participation in the 
TXs pathways, their effects on COX and LOX enzymes, 
and their effects in many transcription factors [90].
In conclusion, since the role of lipids and/or FAs in 
cancer has been outlined and has already been dem-
onstrated, it can be inferred that with the progress of 
lipidomics, understanding the underlying molecular 
machinery of lipid metabolism, and the role of lipids 
would assist the discovery of novel and potential targets, 
and develop new anticancer drugs for cancer therapy [76, 
80, 87, 92]. Likewise, knowing the potential of n-3 LC-
PUFAs to fight cancer, the inclusion of dietary sources of 
these PUFAs, such as fish, will direct the balance towards 
a healthy status rather than a cancer inducing diet char-
acterized by reduced n-3 LC-PUFAs, containing elevated 
levels of dietary saturated fat, n-6 FAs, and hydrogenated 
trans-fats as it is often the case.
Lipids and neurodegenerative disorders
Neurodegeneration is the progressive loss of structure or 
function of neurons, including death of neurons. Many 
neurodegenerative diseases including amyotrophic lat-
eral sclerosis, Parkinson’s, Alzheimer’s, and Huntington’s 
occur as a result of neurodegenerative processes. Aging 
is a natural process that affects the integrity of the neu-
rovascular system, losing its functions and producing 
neurodegenerative diseases [93]. Such diseases are incur-
able, resulting in progressive degeneration and in some 
instances death of neuron cells. To date, more than 600 
neurodegenerative disorders are known. They are clas-
sified according to the brain region, affected cell type or 
the specific molecular markers of each disorder. Genetic 
studies have discovered a wide range of molecular mark-
ers related to neurodegenerative diseases which improves 
the elucidation of molecular mechanisms [94], diagnosis 
and therapeutic procedures [95].
The central nervous system (CNS) is highly enriched 
in n-3 LC-PUFAs, of which DHA is the most impor-
tant, participating in many crucial processes within the 
mammalian cells, as well as being the most abundant 
component of the neuron membrane, having important 
structural and functional roles. Membrane status affects 
the transfer of neuronal information, speed of signal 
transduction, and interaction with proteins, indicating 
the importance of this FA in order to gain appropriate 
functioning [96]. DHA is also the principal n-3 FA in cor-
tical gray matter, representing ~15% of total FAs in the 
adult human prefrontal cortex (PFC). Moreover, other 
FAs like EPA, and less importantly DPA, are also pre-
sent in the CNS, constituting around 1% of total brain FA 
composition [97] (and references within). Therefore, the 
control of the amount of DHA in our body, and especially 
in our liver and brain is really crucial for an optimal brain 
nutrition and functionality.
Alzheimer’s disease (AD) is a neurodegenerative dis-
order that produces severe cognitive impairment as it 
progresses. This pathology is the main neurological cause 
of dementia suffered by 36 million people worldwide, 
elderly adults in most cases (World Alzheimer Report 
2011) [98]. The molecular phenotype is characterized by 
the accumulation of amyloid β peptide (Aβ) and aggre-
gates composed of the hyperphosphorylated microtu-
bule-associated tau protein [99].
Regarding lipids, DHA exerts a neuroprotective mode 
of action together with its lipoxygenase metabolite, Neu-
roprotectin D1. They have been shown to participate in 
many different processes including reductions in pro-
inflammatory signalling (prostaglandin E2 synthesis), 
activation of important genes like Bcl-2, Bcl-xl, Bfl-1, 
which participate in antiapoptotic mechanism, and also 
reducing the expression of proapoptotic genes (Bax, 
Bad) [100]. In this sense, the relationship between DHA 
deficiency and neuropathology in the pre frontal cortex, 
and how n-3 FAs deficiency may increase vulnerability to 
patients suffering affective disorder have been reviewed 
[97]. For example, it has been observed that patients 
with major depressive disorder (MDD), or bipolar disor-
der (BD) exhibit a deficit of DHA in erythrocytes (MDD, 
−20%; BD −32%) relative to healthy controls [101].
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Regarding AD, statistical differences in the amount of 
DHA in the liver of control subjects (324.83  ±  122.89) 
and those of patients with Alzheimer’s disease 
(204.64  ±  74.62) have been reported. These data cor-
related with both a lower amount of DHA in the brain, 
and a lower expression level of two genes involved in 
DHA biosynthesis in liver, fds2 and helo1 [102]. In post-
mortem neocortex tissue, the profile of different lipids 
was investigated through GC–MS analysis. The results 
showed significant higher levels of FAs in AD neocor-
tex region brain samples compared to non-AD neocor-
tex region brain samples. A total of 9 FAs were elevated, 
with a marked increase in the percentage of DHA being 
observed in the cerebral region of AD patients [103]. This 
contrasted with most other reports of brain samples from 
AD individuals, which indicated a drop in DHA or an 
unaltered level in different regions of the brain [104, 105]. 
This increase may be due to the anti-inflammatory capac-
ity of DHA, which may appear increased to activate the 
anti-inflammatory defence mechanism in AD brain.
FA profiles in plasma also seem to be important and 
were quantified and compared with three different cor-
tical regions in brains of deceased participants of the 
Memory and Aging Project. The percentage of DHA was 
lower in both the mid-frontal cortex and superior tem-
poral cortex of AD brains compared to non-impaired 
brains, but only in the phosphatidylserine fraction. 
Furthermore, in plasma the differences in FA profiles 
between AD and non-impaired samples was related to 
the free FA (lower oleic acid isomers and omega-6 FAs in 
AD) and phospholipids (lower omega-3 FAs in AD), sug-
gesting that the level of DHA in plasma is directly related 
with AD [104]. On the other hand EPA, which commonly 
displays 250–300 times lower level in the brain compared 
to DHA, appears preferably esterified to phosphatidylin-
ositol (PI) [106], and plays also an important role in AD. 
It was shown that higher plasma levels of EPA, but not 
DHA, were connected with lower gray matter atrophy, 
suggesting that EPA might play an important role in cog-
nitive decline. Higher EPA levels were also found in the 
right amygdale, and may be associated with depressive 
symptoms [107].
Within the brain, there exist glial cells comprising 
microglia and astrocytes. Although the role of glial cells 
in AD pathology is not clear, they are supposed to give 
support to neurons by removing amyloid β peptides from 
the brain, and also modulate inflammation [108]. Dys-
function of these cells may be related to AD develop-
ment through accumulation of amyloid β peptide. Since 
DHA can modulate glial cell activity, it was considered 
that dietary supplement of DHA may positively modu-
late the effects of Alzheimer [109]. It has been reported 
that the polymerization of Aβ monomers incubated with 
DHA was significantly inhibited (40%). DHA was also 
able to inhibit fibril formation [110]. These authors also 
reported that the level of DHA in the hippocampus of the 
Aβ-infused AD rats was significantly lower than in con-
trol, and how the subsequent DHA administration mark-
edly helped to significantly increase the level of DHA. A 
mechanism of fighting AD is the clearance of amyloid 
β, which has been suggested to delay or even prevent 
AD symptoms. A very interesting recent investigation 
showed that DHA and EPA mediate degradation of Aβ by 
stimulating and boosting the gene expression of insulin-
degrading enzyme (ide), resulting in a higher amount of 
IDE, the major Aβ-degrading enzyme secreted into the 
extracellular space of neuronal and microglial cells [111].
Another interesting fact regarding Aβ and its plasmatic 
accumulation has been recently described. The offspring 
of rats exposed to n-3 and n-6 PUFA enriched diets 
showed a significant increase in plasmatic Aβ levels com-
pared to control when their diet was n-6 PUFA-enriched, 
and decreased levels when a high n-3 PUFA diet was sup-
plied. This accumulation is related with hyper-activation 
of the HPA axis, alteration of cortical monoamine con-
tent, and an induced depressive- and anxiety-like state in 
adult offspring. Altogether these data endorse the posi-
tive and protective role of an n-3 rich diet [112]. The rela-
tionship between soluble Aβ and depression in AD is still 
considered as a hotspot in AD investigation; in fact, the 
effects of soluble Aβ accumulation and depression have 
been widely reported highlighting the strong relationship 
[113–115].
Hashimoto and collaborators have investigated the 
effect of DHA in human neuroblastoma cells (SH-
SY5Y). These cells display a considerably lower content 
of DHA (2.15 ±  0.25  mol%) compared to that found in 
normal neuronal cells (DHA  >  10% of total FAs). The 
authors observed that DHA inhibits the in vitro fibrilla-
tion of Aβ25−35 with a parallel inhibition of neurotoxic-
ity induced by the formation of fibrils. In the presence of 
DHA, the degree of fibrillation significantly decreased by 
about 43%. However, when the Aβ25−35-treated SH-SY5Y 
cells were examined after treatment with DHA, the data 
indicated that the addition of DHA to the cells prevented 
the toxicity of Aβ25−35 [116].
Furthermore, it has been reported that fat-1 trans-
genic mice, which express more n-3 PUFAs (total n-3 
PUFAs in WT: 17.51, in fat-1 mice: 23.45), are more 
resistant to intra cerebroventricular injection of Aβ, 
which induces neuronal cell loss and impairment of 
hippocampus-dependent memory [117]. Similar to the 
results found in fat-1 mice, the clearance of interstitial 
Aβ was much faster in those mice treated with fish oil, 
compared to untreated mice. Such a protective effect 
has been suggested to occur through an activation of the 
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AQP4-mediated glymphatic system to promote intersti-
tial Aβ clearance [118]. DHA, as a fundamental compo-
nent of neuronal membranes, has been widely studied 
as an active compound to treat Alzheimer effects [119]. 
It has been shown that the novel hydroxyl-derivative of 
DHA (OHDHA) has a strong therapeutic potential to 
treat AD. It has been demonstrated that administra-
tion of OHDHA increases the concentration of PUFAs-
containing phospholipids (e.g. DHA or EPA-containing 
phospholipids). The increase in n-3 PUFAs in transgenic 
mouse model of AD was accompanied by a parallel 
reduction in amyloid-β accumulation, which is strongly 
correlated with synaptic degeneration, and with mem-
ory failure and learning deficiencies [98] (and references 
within). DHA asserts its protective role through its stere-
oselective bioactive product Neuroprotectin D1 (NPD1), 
which exerts anti-inflammatory and survival signalling in 
Alzheimer’s disease [120].
Parkinson’s disease (PD), was first medically described 
as a neurological syndrome by James Parkinson in 1817. 
It is a progressive neurodegenerative disease character-
ized by loss of dopaminergic neurons containing neu-
romelanin in the substantia nigra pars compacta (SNpc) 
[121]. The common symptoms include tremor, rigidity, 
bradykinesia and postural insecurity, with dementia and 
depression observed in the advanced stages of the dis-
ease. It is known that a decline in FA concentration is 
observed in neurodegenerative diseases, such as PD, and 
it could be expected that n-3 PUFAs may exert neuropro-
tective action in PD, as previously shown in Alzheimer’s 
disease. It has been described that PUFAs are known 
to play an important role in lowering anxiety and also 
improving cognitive functions in non-human primates 
[122].
One study investigated the effect of the neurotoxin 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
when given to mice (from 2 to 12  months of age) fed a 
diet high in n-3 PUFAs. It was observed that the rich n-3 
PUFA diet protected against the MPTP-induced decrease 
in dopamine, and its metabolite dihydroxyphenylacetic 
acid in the striatum. These data suggest that a high n-3 
PUFAs dietary intake might exert neuroprotective 
actions in an animal model of Parkinson disease [123].
Within LC-PUFAs, DHA is the most important one 
for the brain; recently, in an experimental mouse model 
of PD the effects of the neurotoxin MPTP administrated 
together with DHA were evaluated. The results indi-
cated that DHA has protective effects on dopaminer-
gic neurons in this MPTP-induced experimental model 
[124]. Transgenic animal models have also been used 
to test the protective effect of high levels of n-3 PUFAs. 
Bousquet and collaborators published that the expres-
sion of the fat-1 transgene (which encodes the enzyme 
n-3 PUFA desaturase that catalyzes the n-6 to n-3 PUFA 
conversion) in mice increased the cortical n-3:n-6 PUFA 
ratio (+28%) compared to control. This modification 
is less effective than a dietary supplementation, since 
a 10-month exposure to an n-3 PUFA-enriched diet 
increased the n-3:n-6 PUFA ratio by as much as 92%. 
Regarding neuroprotection in animal models of PD using 
MPTP, the data suggest that dietary intake of a preformed 
DHA supplement is more effective than the expression of 
the fat-1 transgene [125].
The preventing effect of DHA on dopaminergic lesion 
was also studied by determining the levels of tyrosine 
hydroxylase (TH) in MPTP and MPTP +  DHA treated 
cells [126]. There was a 65% decline in the number of 
TH-immunopositive neurons in the substancia nigra 
one week after MPTP administration and the num-
ber of TH-positive neurons significantly increased in 
the MPTP +  DHA group compared to the MPTP con-
trol group. DHA may block the conversion of MPTP to 
MPP+ or prevents the uptake of MPP+ into dopamin-
ergic terminals. This study suggested that dietary sup-
plementation with DHA may be a potential means for 
delaying the onset of PD and/or the rate of progression 
[126].
One-third of PD patients suffer depression that may 
lead to worse health outcomes, and a decreased quality 
of life. Anxiety, apathy and anhedonia further complicate 
PD outcomes. DHA was tested as a therapy to reduce 
these symptoms. It was observed that 75% of PD patients 
treated with DHA and EPA (DHA, 800  mg/day, EPA 
290 mg/day) for 6 months showed a reduction of at least 
50% on the Hamilton Rating Scale for Depression, com-
pared with only 25% into the placebo group. These data 
suggest that a combination of DHA and EPA can reduce 
the depressive symptoms of PD [127]. A similar study 
regarding depression using the Hoehn and Yahr scale did 
not however show a significant variation in all groups 
during a 3  month trial using fish oil supplements (con-
taining omega-3 FAs). However, when the patients were 
evaluated for depression symptoms using the Montgom-
ery–Asberg Scale, it was observed that after 3-month 
supplementation, fish oil groups, taking or not antide-
pressant medication, exhibited a reduction in depression 
symptoms when compared to mineral oil groups [128].
It has been demonstrated that DHA stimulates the pro-
duction of syntaxin 3 (STX3), a plasma membrane pro-
tein that has an important role in the growth of neuritis 
in PC12 cells and hippocampal neurons cultures. This 
protein is directly activated by ARA, but DHA also serves 
as an activator of STX3. Therefore, DHA can efficiently 
substitute dietary ARA in activating syntaxin 3 [129]. 
Regarding dietary omega-3 FAs, it has been shown that 
the combination of voluntary exercise potentiated the 
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effects of DHA after 12-day dietary supplementation 
with a resulting increase of STX3. Levels of STX3 were 
stimulated separately by both DHA diet (150% compared 
to control) and exercise (126% compared to control). 
It should be highlighted that the combination of DHA 
diet and exercise regimens showed an up-regulation of 
STX3 levels (186% of control) [130]. These authors have 
also published that DHA and exercise positively affect 
the levels of the NMDA receptor subunit NR2B, which is 
important for synaptic function underlying learning and 
memory. Together DHA and exercise boost NR2B levels 
up to 169% compared to control, while DHA and exercise 
separately were able to elevate the levels of NR2B to 145 
and 123% respectively, compared to the controls [130]. 
All these data suggest that exercise can influence the 
effect of DHA on neuron membrane function, and help 
to maintain synaptic and cognitive function by support-
ing membrane stability.
Amyotrophic lateral sclerosis (ALS) is a rare group of 
neurological diseases that mainly involve the nerve cells 
(neurons) responsible for controlling voluntary muscle 
movement. The disease is progressive, in which symp-
toms get worse year after year. Unfortunately, there 
is neither a cure nor an effective treatment to halt, or 
reverse, the progression of the disease. Membranes from 
motor neurons and other neurons in the CNS possess 
the highest amounts of PUFAs. They play an important 
role in the maintenance and function of the membrane 
by acting through a variety of molecular mechanisms 
[131]. A recent study in a mouse model of ALS (G93A-
mutated human superoxide dismutase) has identified a 
relationship between neuronal loss and DHA levels. In 
this mouse model a significant decrease in DHA-contain-
ing phosphatidylcholines (PCs), in the terminal stage of 
ALS was shown [132]. Using MALDI-IMS analysis, the 
authors observed that the mean signal intensities corre-
sponding to PC (diacyl-16:0/22:6) in the anterior horn in 
L5 spinal cord sections of 22-week-old mice model were 
significantly lower than those in the age-matched control, 
and this lost was related with motor neuron cell death.
It is known that ALS related protein oxidative damage 
affects FA concentrations specifically the n-3 series [133]. 
For example DHA levels were 30% lower in spinal cord 
samples from ALS patients compared to control. This 
data surprisingly contrasts with the significant increase 
(18%) observed in frontal cortex samples. TDP-43 pro-
tein, a transcriptional repressor, is found as cytosolic 
aggregates in sporadic ALS. It is known that in ALS, 
TDP-43 protein pathologies are related with oxidative 
stress in which ERK1/2 pathway is involved [134]. It has 
been published that cytosolic aggregates of TDP-43 pro-
tein associated with ALS produced in the spinal cord 
showed a lower expression of some DHA synthesizing 
enzymes, such as ACAA1, FADS1 and COX1. The 
authors analyzed the tissular concentration of these 
enzymes observing that in the spinal cord, the enzymes 
involved in FA β-oxidation like ACAA1 and ACAA2, as 
well as those related to early steps of FA desaturation, like 
FADS2, were all increased in the analyzed ALS samples 
(ranging between 20 to 110%) [135].
A dietary intake of omega-3 is really important in ALS, 
as well as in Alzheimer or Parkinson. In a large analysis 
of a total of 995 ALS patients fed with an omega-3 PUFA 
enriched diet, this intake was associated with a risk 
reduction of 34% for ALS. Further analysis of the individ-
ual omega-3 PUFAs established that intakes of ALA and 
marine n-3 PUFAs, were each associated with a lower 
ALS risk [136].
Inflammatory processes that destroy motor neurons 
in the spinal cord, brain stem and cortex during ALS 
could be reduced by DHA administration due to its 
potent anti-inflammatory properties. It is known that 
DHA increases total glutathione levels in microglia 
cells, thus enhancing their antioxidative capabilities. In 
parallel, DHA causes a reduction of pro-inflammatory 
cytokines, such as IL-6 or TNF-α. Furthermore, Poly 
I:C, a toll-like receptor (TLR) agonist, has the capacity 
of increasing the secretion of IL-6 produced by micro-
glia. Poly I:C is able to mimic a viral or bacterial infec-
tion through activation of TLR pathway, which are 
considered the first line of defence against viral and bac-
terial pathogens. Stimulation of an immortalized mouse 
brain cell line (EOC20 microglia) with Poly I:C causes 
an increase in IL-6; however, a 24 h pre-treatment with 
DHA resulted in a lowering of IL-6 to undetectable lev-
els, indicating the inhibiting capacity of DHA of pro-
inflammatory cytokines [137].
In another mouse model however, n-3 PUFAs could 
also act negatively, stimulating the symptoms of ALS pro-
gression as well as lipid peroxidation compared to con-
trol [138]. Feeding pre-symptomatic mice (G39A-SOD1) 
EPA (300 mg/kg/day), for 6 weeks increased lipid peroxi-
dation. Higher amounts of 4-hydroxy-2-hexenal, a toxic 
and reactive aldehydic intermediate formed by nonenzy-
matic peroxidation of n-3 PUFAs, were detected in the 
entire gray matter of sporadic ALS [139]. The increment 
of 4-hydroxy-2-hexenal could result in an increased oxi-
dative stress in microglia and could also be related with a 
decrease in microglia cell number [138].
Altogether this information indicates that n-3 PUFAs, 
particularly DHA, are crucial for the development, main-
tenance and function of the CNS and should be included 
in our diet. Moreover, further investigation should be 
carried out in order to determine the LC-PUFAs molecu-
lar and physiological mechanisms participating in neuro-
degenerative diseases affecting humans.
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Diet as a tool to acquire functional lipids and to 
maintain health
Food is part of our daily activity, and of vital importance 
for the maintenance of life. The relevance of omega-3 
LC-PUFAs, particularly EPA and DHA, in human nutri-
tion and health has been emphasized. Briefly, LC-PUFAs 
including ARA are the predominant components of the 
75–88% of the phospholipids constituting the cell mem-
brane bilayer in animals. They play a central role in 
almost all physiological and biochemical events within 
the cells, and therefore, in maintaining optimal cellular 
function [140, 141].
It is widely accepted that for attaining a healthy status 
a balanced omega-6 to omega-3 ratio in our diet is more 
essential than the absolute amounts of individual FAs. In 
the diet of early humans, the proportion between both 
groups of FAs was maintained close to 1:1. However, in 
present-day Western diets, characterised by a high intake 
of saturated fats, n-6 FAs, detrimental trans-FAs, and ele-
vated consumption of sugars, this ratio has risen to 20:1 
or even higher, leading to continuous daily intakes that 
are far away from the optimal acquisition of healthy n-3 
FAs. This imbalance favours obesity and has been proven 
to be prothrombotic and proinflammatory [25, 142], 
which stimulates a myriad of inflammatory dependent 
ailments, such as arthritis, cancer, hypertension, diabe-
tes, asthma, atherosclerosis, Alzheimer, Parkinson, aller-
gies and many more [27, 28, 143].
Although mammals, including humans, possess the 
biochemical machinery and enzymes to fabricate LC-
PUFAs from their C18 precursors, they are unable to de 
novo biosynthesize the essential fatty acids ALA and LA, 
which can only be attained through diet. Although some 
ALA is converted to the longer-chain omega-3 FAs, the 
extent of this conversion is modest. Thus, in  vivo stud-
ies in humans reported that ca. 5% of ALA was converted 
to EPA and ca. 0.5% of ALA was converted to DHA 
[20], indicating the low ability to produce these impor-
tant FAs. Interestingly, another recent report shows that 
although the conversion of ALA into DHA is not very 
efficient (<1%), the addition of supplemental ALA, which 
did not significantly increase the detected amounts of 
DHA in plasma or erythrocytes unlike EPA that did aug-
ment upon ALA feeding, appeared to be sufficient to 
sustain brain function. Moreover, it was determined that 
extremely low ALA dietary intakes are required to sig-
nificantly affect brain DHA levels and function, assum-
ing however, that the neurological impairments observed 
with ALA deficiency are caused by the decrease of DHA 
in brain [144]. Overall, it is widely accepted that the bio-
synthetic pathway in humans does not provide sufficient 
levels of ALA because of being, together with LA, essen-
tial FAs, to meet EPA and DHA demands and therefore, 
a dietary intake of preformed omega-3 LC-PUFAs is 
needed.
Recommendations of consumption and/or supplemen-
tation of these omega-3 FAs are specific to particular 
groups of age and physiological status, and still require 
further study to be adequately established. However, most 
health bodies and Government agencies recommend con-
suming between 250 and 1000 mg of EPA + DHA per day 
for adults, to maintain health and well-being [145]. Par-
ticularly, the Food and Agriculture Organization (FAO) of 
the United Nations jointly with the World Health Organi-
zation (WHO), and the European Food Safety Authority 
(EFSA) recommend a daily EPA + DHA intake of at least 
250 mg. On the other hand, the lower limit for the health 
of a general adult population set by the UK Government 
is 450 mg EPA + DHA/day [47, 146, 147]. These amounts 
should be increased up to 1–1.5 g/day for cardiovascular 
disease (CVD) risk reduction or patients with hypertri-
glyceridemia [145]; although the real benefit of this rec-
ommendation is sometimes controversial [148].
Human milk is a source of LA, ALA, ARA, EPA, 
DHA and other LC-PUFAs. While the level of ARA 
remains relatively constant, that of DHA is more vari-
able and depends on maternal diet and lifestyle. Dur-
ing pregnancy, increased maternal dietary requirements 
of omega-3 FAs occur because of fetal accretion [149]. 
Enhanced maternal n-3 FA intakes during pregnancy and 
lactation may result in an increase in the duration of ges-
tation and infant size at birth, reducing the incidence of 
preeclampsia and postpartum depression. In addition, 
some evidences from both observational studies, and 
interventional trials suggest that a higher n-3 LC-PUFAs 
supply was associated with beneficial effects on infant 
growth and neurodevelopment [150]. Pregnant and lac-
tating women achieving an average daily dietary DHA 
intake of at least 150–200 mg up to about 1200 mg, pro-
longed gestation, increased birth weight, and reduced the 
risk of preterm delivery before 34 weeks of gestation by 
31% in all pregnancies or by 61% in high-risk pregnan-
cies. No adverse effects were registered apart from some 
cases of belching or unpleasant taste, even at the high-
est dietary levels assayed of 1.2  g/day of DHA or 2.7  g/
day of total n-3 LC-PUFAs [150]. In a recent review, the 
relationship between reduced maternal consumption of 
n-3 PUFAs, and the prevalence of childhood and adoles-
cence neuropsychiatric condition including autistic spec-
trum disorders (ASD), attention deficit disorders (ADH), 
schizophrenia spectrum disorders (SSD), and depression 
and anxiety disorders has been highlighted [151].
In summary, a minimum daily intake of 300  mg/day 
of EPA + DHA, of which 200 mg/day are DHA or up to 
700–1000 mg of EPA + DHA/day is highly recommended 
for a more favourable pregnancy and lactation [145].
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The diets of vegetarian (those avoiding all meat) and 
vegan (those completely avoiding animal-based products) 
have been associated with markedly lower levels of DHA 
in plasma phospholipids. In vegetarians, ALA supple-
mentation was demonstrated to increase the proportion 
of EPA but not DHA. It would thus appear that only sup-
plementation with preformed DHA reliably increases tis-
sue DHA. On the other hand, although vegans had zero 
intake of preformed DHA, it was nevertheless present in 
blood phospholipids, suggesting basal conversions from 
ALA to DHA that may be up-regulated by the absence 
of—and down-regulated by the presence of—dietary 
preformed DHA [19]. In line with this, breast milk DHA 
cannot be increased with the addition of ALA or other 
DHA precursors to the diet, hence the breast milk of 
strict vegans contains the lowest DHA amount compared 
to that of fish-eaters or vegetarians [152].
Fish oil is the largest source of EPA and DHA, while 
eating fish constitute the major way of ingesting these 
functional FAs in human diets. A modest consump-
tion of 2–3 servings of fish per week, particularly oily 
fish such as salmon, tuna, herring, mackerel or sardines, 
can be enough to meet most intake recommendations 
for healthy status (Table  1). There has been a continu-
ous increase in the apparent fish consumption (kg per 
capita) from 9.9 kg in the 1960s to 14.4 in the 1990s, and 
to beyond 20.0  kg in 2015 [153]. This increase corre-
lates with the concomitantly higher omega-3 FAs intake 
within this period. This increment is in part due to the 
significant growth in fisheries and aquaculture products 
as a whole, and to the raising awareness of the world’s 
population to the benefits of fish consumption for human 
health. However, fish is a declining resource, with a dis-
quieting 58.1% of all fish stocks being overfished, and 
more than 26% of stocks fished at biologically unsustain-
able levels [153]. With capture fishery production being 
relatively static at around 80–90 million tonnes per year 
since the late 1980s, aquaculture has been proposed by 
the FAO as the potential complement to meet the grow-
ing demand for marine based alimentation. In fact, the 
aquaculture contribution to the supply of fish for human 
consumption overtook that of wild-caught fish in 2014 
for the first time [153]. At present, one of the major chal-
lenges for the aquaculture industry is the environmen-
tal sustainability of the activity. New sustainable and 
environmentally friendly ingredients for aquafeeds are 
needed, that do not compromise the nutritional benefits 
of fish consumption for humans.
Fish recommendation must also be balanced with 
concerns about environmental pollutants. Larger fish 
predators may contain significant levels of methyl mer-
cury, and other potentially harmful contaminants, such 
as polychlorinated biphenyls (PCBs) and dioxins that 
bioconcentrate in the aquatic food chain. Children and 
pregnant or lactating women may be at a higher risk of 
mercury intoxication from fish consumption and thus, 
it seems prudent to avoid consuming large quantities of 
higher fish predators. The consumption of a variety of 
fish species is the best approach to both minimizing mer-
cury exposure and increasing omega-3 FAs intake [48].
None fish-eaters, or those who just want an extra boost, 
may ingest omega-3 supplements. Marine microorgan-
isms are the major source for consumption and for the 
production of encapsulated fish oil. Fish oil is commer-
cially available mainly as soft gel capsules often includ-
ing added vitamins, antioxidants, and various flavours. 
However, capsules should be taken under medical super-
vision, because taking fish oil can cause a number of gas-
trointestinal disturbances, including belching, heartburn, 
nausea and loose stools. In addition, people under the 
age of 18 years, and pregnant or lactating women should 
not take fish oil capsules unless under the supervision 
of a doctor. To minimize possible adverse side effects, 
these supplements should be stored in the refrigerator 
Table 1 Amounts of  total fat, EPA, DHA and  EPA +  DHA 
(g/100  g of  serving) in  fish species of  different origin 
and processing
Fish name Total fat EPA DHA EPA + DHA
Atlantic mackerel (cooked) 17.8 0.504 0.699 1.203
Greenland halibut (cooked) 17.7 0.670 0.504 1.178
Chinook salmon (cooked) 13.4 1.010 0.727 1.737
Atlantic salmon (farmed) 12.4 0.690 1.457 2.147
Atlantic herring (cooked) 11.6 0.909 1.105 2.014
Red salmon (cooked) 11.0 0.530 0.700 1.230
Pacific sardine (canned in 
tomato)
10.5 0.532 0.865 1.397
European anchovy (canned in 
vegetable oil)
9.7 0.763 1.292 2.055
Atlantic salmon (wild, cooked) 8.1 0.411 1.429 1.840
Rainbow trout (farmed and 
cooked)
7.2 0.334 0.820 1.154
Red tuna (fresh or cooked) 6.3 0.363 1.141 1.504
Rainbow trout (wild and cooked) 5.8 0.468 0.520 0.988
Sword fish (cooked) 5.1 0.138 0.681 0.819
Atlantic and Pacific halibut 
(cooked)
2.9 0.091 0.374 0.465
Channel catfish (wild, cooked) 2.9 0.100 0.137 0.237
European pollock (cooked) 1.9 0.076 0.162 0.238
Mere fish various sp. (cooked) 1.3 0.035 0.213 0.248
Shrimp various sp. (cooked) 1.1 0.171 0.144 0.315
Atlantic cod (cooked) 0.9 0.004 0.154 0.158
Tuna (canned in brine) 0.8 0.047 0.223 0.270
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or freezer and kept away from light, and should be taken 
when they are cold in order to reduce undesirable stom-
ach upset symptoms.
As fish oil production is currently declining, other 
sources of omega-3 LC-PUFAs are currently being evalu-
ated. Micro and macroalgae, some of them with valu-
able nutritional FA profiles, are already under industrial 
exploitation after optimization of culture and growth 
medium conditions [154]. Other promising sources of 
omega-3 essential FAs such as zooplankton, commonly 
known as “krill”, fungi, and genetically modified plants 
must overcome many challenges, such as cost, environ-
mental concerns, consumer acceptance, viability and sen-
sory quality prior to their consolidation [148].
Conclusions
Undoubtedly lipidomics has allowed tremendous 
advances in understanding and determining the true 
importance of lipids and FAs in many physiological and 
molecular mechanisms implicated in the establishment 
of healthy or diseased status.
There is compelling evidence that omega-3 LC-PUFAs, 
particularly EPA and DHA, and an adequate balance of 
omega-6/omega-3 FAs play a determinant role in most 
physiological and biochemical processes occurring in 
cells and organisms, having great significance in decreas-
ing the risk of many diseases or even resolving their 
inherent inflammation condition. This has been broadly 
driven by the impressive development of technologies 
applied to lipidomics, and the subsequent understand-
ing of the underlying molecular mechanisms of lipid 
metabolism.
Nutritional recommendations, based on epidemio-
logical evidence, have been advocated by many health 
authorities, and agencies to reduce both, the excessive 
intake of omega-6 PUFAs, and the very high omega-6/
omega-3 ratio of current diets. Thus, consumption of 
higher amounts of fish, the main source of biologically 
important omega-3 LC-PUFAs in combination with 
natural antioxidants is strongly recommended. In this 
sense, and although a more fine-tuning is still needed to 
particular groups of age and physiological status, 450–
500 mg of EPA + DHA per day is suggested for general 
health condition of the adult population. This could be 
met with a weekly ingestion of 2–3 portions of oily fish. 
Increased amounts of up to 1 to 3–4  g/day of omega-3 
LC-PUFAs should be ingested during pregnancy and lac-
tation or to prevent most cardiovascular, neurodegenera-
tive and proinflammatory disorders.
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